Recently, seromic profiling of colorectal cancer patients with a glycopeptide microarray identified abs to aberrant glycopeptides derived from MUC1 and MUC4 that may be of use for colorectal cancer screening [82,83]. Here, MUC4 is linked to colorectal cancer.